| 123.96 0 (0%) | 07-15 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 144.82 | 1-year : | 169.15 |
| Resists | First : | 123.98 | Second : | 144.82 |
| Pivot price | 123.83  |
|||
| Supports | First : | 123.52 |
Second : | 123.23 |
| MAs | MA(5) : | 123.95 | MA(20) : | 123.75 |
| MA(100) : | 107.84 |
MA(250) : | 99.05 |
|
| MACD | MACD : | 2.5 |
Signal : | 3.2 |
| %K %D | K(14,3) : | 94.6 | D(3) : | 94.6 |
| RSI | RSI(14): 67.5 | |||
| 52-week | High : | 123.98 | Low : | 71.12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NUVL ] has closed below upper band by 28.4%. Bollinger Bands are 96.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 124.25 - 124.86 | 124.86 - 125.36 |
| Low: | 122.22 - 123.08 | 123.08 - 123.77 |
| Close: | 122.78 - 124.06 | 124.06 - 125.09 |
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Mon, 24 Aug 2026
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating Growth Potential Amidst a Steady Market Position - DirectorsTalk Interviews
Wed, 15 Jul 2026
Nuvalent (NASDAQ: NUVL) tender offer clears $124 cash merger path - Stock Titan
Wed, 15 Jul 2026
Nuvalent Inc. (NASDAQ: NUVL) Holders Tender 91% in $124 GSK Deal - Stock Titan
Wed, 24 Jun 2026
GSK announces commencement of tender offer to acquire Nuvalent, Inc. - GSK
Tue, 09 Jun 2026
NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company? - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 113.3 (%) |
| Shares Short | 2,910 (K) |
| Shares Short P.Month | 5,240 (K) |
| EPS | -6.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.6 % |
| Return on Equity (ttm) | -41.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -313 (M) |
| Levered Free Cash Flow | -180 (M) |
| PE Ratio | -20.46 |
| PEG Ratio | 0 |
| Price to Book value | 8.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|